[go: up one dir, main page]

LT3321287T - Sulieti baltymai ir sudėtinės vakcinos - Google Patents

Sulieti baltymai ir sudėtinės vakcinos

Info

Publication number
LT3321287T
LT3321287T LTEP17201766.7T LT17201766T LT3321287T LT 3321287 T LT3321287 T LT 3321287T LT 17201766 T LT17201766 T LT 17201766T LT 3321287 T LT3321287 T LT 3321287T
Authority
LT
Lithuania
Prior art keywords
fusion proteins
combination vaccines
vaccines
combination
fusion
Prior art date
Application number
LTEP17201766.7T
Other languages
English (en)
Inventor
Normand Blais
Steve Labbe
Jan Poolman
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47008755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3321287(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of LT3321287T publication Critical patent/LT3321287T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP17201766.7T 2011-04-13 2012-04-12 Sulieti baltymai ir sudėtinės vakcinos LT3321287T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474779P 2011-04-13 2011-04-13
US201161534012P 2011-09-13 2011-09-13

Publications (1)

Publication Number Publication Date
LT3321287T true LT3321287T (lt) 2020-06-10

Family

ID=47008755

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17201766.7T LT3321287T (lt) 2011-04-13 2012-04-12 Sulieti baltymai ir sudėtinės vakcinos
LTEP12771540.7T LT2707393T (lt) 2011-04-13 2012-04-12 Sulietų baltymų ir vakcinų deriniai, apimantys haemophilus influenzae baltymą e ir piliną a

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP12771540.7T LT2707393T (lt) 2011-04-13 2012-04-12 Sulietų baltymų ir vakcinų deriniai, apimantys haemophilus influenzae baltymą e ir piliną a

Country Status (36)

Country Link
US (7) US8945577B2 (lt)
EP (2) EP2707393B1 (lt)
JP (1) JP6196963B2 (lt)
KR (1) KR101999673B1 (lt)
CN (3) CN107522788A (lt)
AR (1) AR086078A1 (lt)
AU (1) AU2012243412C1 (lt)
BR (1) BR112013026175B1 (lt)
CA (1) CA2830786C (lt)
CL (1) CL2013002937A1 (lt)
CO (1) CO6781540A2 (lt)
CR (1) CR20130529A (lt)
CY (2) CY1120319T1 (lt)
DK (2) DK3321287T3 (lt)
DO (1) DOP2013000235A (lt)
EA (1) EA031580B1 (lt)
ES (2) ES2776369T3 (lt)
HR (2) HRP20180216T1 (lt)
HU (2) HUE048848T2 (lt)
IL (2) IL271862B (lt)
LT (2) LT3321287T (lt)
MA (1) MA35110B1 (lt)
ME (1) ME02995B (lt)
MX (1) MX350013B (lt)
PE (1) PE20140986A1 (lt)
PH (1) PH12013502121A1 (lt)
PL (2) PL3321287T3 (lt)
PT (2) PT3321287T (lt)
RS (1) RS56903B1 (lt)
SG (2) SG193906A1 (lt)
SI (2) SI2707393T1 (lt)
SM (1) SMT201800125T1 (lt)
TW (1) TW201302779A (lt)
UY (1) UY34017A (lt)
WO (1) WO2012139225A1 (lt)
ZA (1) ZA201307118B (lt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
EP2908855B1 (en) * 2012-10-17 2017-06-28 GlaxoSmithKline Biologicals S.A. Immunogenic composition comprising 1 or more streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising protein e and/or pila fromhaemophilus influenzae .
HUE046218T2 (hu) 2013-09-30 2020-02-28 Iaf Science Holdings Ltd Rágható termék és eljárás elõállítására
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
CN107532204A (zh) * 2015-01-16 2018-01-02 肯塔基大学研究基金会 脂质双层集成spp1连接子蛋白纳米孔和作为脂质双层集成纳米孔的spp1连接子蛋白变体
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CN110996994A (zh) * 2017-08-14 2020-04-10 葛兰素史密丝克莱恩生物有限公司 加强免疫应答的方法
CN107602697B (zh) * 2017-08-29 2020-05-05 杭州医学院 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
MX2020013623A (es) * 2018-06-19 2021-03-25 Glaxosmithkline Biologicals Sa Composicion inmunogenica.
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CN110540598B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法
CN110540597B (zh) * 2018-12-20 2021-04-30 湖北工业大学 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法
WO2020174044A1 (en) 2019-02-27 2020-09-03 Evaxion Biotech Aps Vaccines targeting h. influenzae
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
MX2022001489A (es) 2019-08-05 2022-03-02 Glaxosmithkline Biologicals Sa Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d.
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
KR20220142219A (ko) * 2021-04-14 2022-10-21 한국생명공학연구원 장내 미생물에서 단백질 분비를 유도하는 신호서열
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0606921B1 (en) * 1989-03-09 2000-08-02 American Cyanamid Company Method of isolating haemophilus influenzae protein E
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
CZ288908B6 (cs) 1995-06-23 2001-09-12 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína, tato vakcína ve formě sady, způsob její výroby a její použití
DE69740108D1 (de) 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
CA2424275A1 (en) 2000-10-02 2002-04-11 Shire Biochem Inc. Haemophilus influenzae antigens and corresponding dna fragments
WO2002083710A2 (en) 2001-04-13 2002-10-24 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0222764D0 (en) 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide
AU2004257228B8 (en) 2003-07-09 2009-01-08 Life Technologies Corporation Method for assaying protein-protein interaction
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
AR053385A1 (es) * 2005-05-12 2007-05-02 Novartis Ag Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
EP1904519B1 (en) * 2005-07-08 2010-11-17 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
DE602006010386D1 (en) * 2005-07-08 2009-12-24 Univ Zuerich Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden
BRPI0614734A2 (pt) 2005-08-10 2011-04-12 Arne Forsgren Ab interação de moraxella catarrhalis com células epiteliais, proteìnas da matriz extracelular e com o sistema de complemento
US8617565B2 (en) * 2006-01-17 2013-12-31 Arne Forsgren et al. Surface exposed Haemophilus influenzae protein (protein E; pE)
GB2444903A (en) * 2006-12-21 2008-06-25 Secr Defence Live Francisella vaccine, inactivated at gene FTT1564
KR20110038047A (ko) 2008-06-20 2011-04-13 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 산화 ＬＤＬ／β２ＧＰＩ복합체에 대한 항체 및 그 용도
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗

Also Published As

Publication number Publication date
EP2707393A1 (en) 2014-03-19
ME02995B (me) 2018-10-20
US20150166613A1 (en) 2015-06-18
MX350013B (es) 2017-08-23
CL2013002937A1 (es) 2014-07-25
ES2658512T3 (es) 2018-03-12
HUE048848T2 (hu) 2020-08-28
AU2012243412A1 (en) 2013-04-18
KR101999673B1 (ko) 2019-07-12
AU2012243412C1 (en) 2015-12-10
WO2012139225A1 (en) 2012-10-18
SG10201602549WA (en) 2016-05-30
PE20140986A1 (es) 2014-08-20
US11198707B2 (en) 2021-12-14
HRP20200466T1 (hr) 2020-06-26
HRP20180216T1 (hr) 2018-03-09
US10730917B2 (en) 2020-08-04
EP2707393B1 (en) 2017-12-20
PH12013502121A1 (en) 2014-01-13
MX2013011939A (es) 2014-03-27
EA201391240A1 (ru) 2014-04-30
SI3321287T1 (sl) 2020-07-31
PL2707393T3 (pl) 2018-05-30
DOP2013000235A (es) 2014-03-16
CY1120319T1 (el) 2019-07-10
PL3321287T3 (pl) 2020-07-27
UY34017A (es) 2012-11-30
EA031580B1 (ru) 2019-01-31
CR20130529A (es) 2014-03-05
NZ615328A (en) 2015-10-30
IL228344B (en) 2020-01-30
US20200331972A1 (en) 2020-10-22
US9296794B2 (en) 2016-03-29
US20180222946A1 (en) 2018-08-09
SI2707393T1 (en) 2018-03-30
US8945577B2 (en) 2015-02-03
EP3321287A1 (en) 2018-05-16
CN103476799A (zh) 2013-12-25
IL271862A (en) 2020-02-27
ZA201307118B (en) 2022-03-30
KR20140026483A (ko) 2014-03-05
SG193906A1 (en) 2013-11-29
ES2776369T3 (es) 2020-07-30
BR112013026175A2 (pt) 2016-11-29
US9409957B2 (en) 2016-08-09
CO6781540A2 (es) 2013-10-31
US10214569B2 (en) 2019-02-26
US10023616B2 (en) 2018-07-17
IL271862B (en) 2022-07-01
HUE036983T2 (hu) 2018-08-28
EP2707393A4 (en) 2014-11-05
DK3321287T3 (da) 2020-05-04
MA35110B1 (fr) 2014-05-02
CY1122824T1 (el) 2021-05-05
LT2707393T (lt) 2018-03-12
CN107522788A (zh) 2017-12-29
IL228344A0 (en) 2013-12-31
AU2012243412B2 (en) 2015-05-14
PT3321287T (pt) 2020-05-22
BR112013026175B1 (pt) 2020-05-12
US20160250313A1 (en) 2016-09-01
PT2707393T (pt) 2018-02-09
US20150175670A1 (en) 2015-06-25
SMT201800125T1 (it) 2018-05-02
DK2707393T3 (da) 2018-01-29
AR086078A1 (es) 2013-11-20
TW201302779A (zh) 2013-01-16
US20170029472A1 (en) 2017-02-02
JP2014512365A (ja) 2014-05-22
CA2830786C (en) 2021-10-26
RS56903B1 (sr) 2018-05-31
JP6196963B2 (ja) 2017-09-13
CN107383201A (zh) 2017-11-24
US20140056934A1 (en) 2014-02-27
EP3321287B1 (en) 2020-02-26
CA2830786A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
PT3321287T (pt) Proteínas de fusão e vacinas de combinação
SG11201400432VA (en) Polypeptide vaccine
ZA201404667B (en) Anticancer fusion protein
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
GB201101140D0 (en) Fused aminodihydrothiazine derivatives
EP2772230A4 (en) FUSION GRAFT
ZA201309399B (en) Peptide carrier fusion proteins as allergy vaccines
SG10201500208SA (en) Npp1 fusion proteins
PL2661496T3 (pl) Przeciwnowotworowe białko fuzyjne
ZA201405460B (en) Anticancer fusion protein
EP2698386B8 (en) Fusion protein
EP2657337A4 (en) FUSION PROTEIN
PL2622078T3 (pl) Białko fuzyjne dla ekspresji białka wydzielniczego
ZA201308597B (en) Anticancer fusion protein
ZA201306245B (en) Combination vaccines
PT2744831T (pt) Proteína de fusão de transferrina-tumstatina e métodos para a produzir e utilizar
ZA201207425B (en) Fusion protein
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins
GB201104152D0 (en) Fusion Polypeptide
GB201007955D0 (en) Somatosatin fusion proteins
AU4710P (en) Fusion xTriticosecale
GB201204065D0 (en) Fusion polypeptide
AU2011905145A0 (en) Fusion Protein
GB201108982D0 (en) Vaccines